1. Viracta Therapeutics reports promising Phase 2 trial results for nanatinostat in treating relapsed/refractory EBV-positive PTCL.

Viracta Therapeutics reported promising Phase 2 NAVAL-1 trial results for its nanatinostat drug in treating relapsed or refractory Epstein-Barr virus-positive peripheral T-cell lymphoma, with an overall response rate of 33% and a complete response rate of 19%. The company plans to focus on the second-line EBV-positive PTCL subpopulation and initiate a randomized controlled trial in 2025 for potential accelerated approval in 2026. To allocate resources, Viracta has paused its EBV+ solid tumor program and reduced its workforce by 23%.

August 14, 2024
3 Articles